Remove 2023 Remove Compounding Remove Dosage
article thumbnail

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

PharmaTech

Related Content Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia Patrick Lavery June 9th 2025 Article The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.

article thumbnail

Common Findings from NABP Pharmacy Inspections

National Association of Boards of Pharmacy

This blog post will identify key areas where gaps were identified against USP compounding chapter standards during VPP inspections in the 12 months after the revised compounding chapters went into effect. Beyond Use Dates for aqueous dosage units exceeded Table 4. Floors were not cleaned daily, when compounding occurred.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Therapeutic Guidelines, Australian Medicines Handbook and APF

RX Note

Beyond these official sources, various healthcare societies and associations also contribute by publishing practical guides relevant to their specific disciplines.

article thumbnail

FDA Mandates Major Opioid Label Revisions to Highlight Long-Term Risks

Pharmacy Times

Suggestions for providers featured in the guidelines include determining if opioids should take place, selecting appropriate dosages, determining prescription length and follow-up, and assessing and reducing risks of misuse, overdose, and opioid use disorder.

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

article thumbnail

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Pharmacy Times

This phase 1b clinical trial, conducted between September 2023 and November 2024, was designed to build on promising preclinical data that demonstrated improved efficacy and tolerability with continuous SC lenalidomide delivery in murine MM models. It will be interesting to see what dosage form these data prompt the future development of.

article thumbnail

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

Pharmacy Times

Lamya Al-Saleh, PharmD, RPh, graduated with the PharmD Class of 2023 from Chapman University School of Pharmacy in Irvine, California. AE Profile In October 2023, the FDA approved a triplet-therapy regimen combining BV, Len, and R for use in the treatment of patients with otherwise unclassifiable R/R DLBCL who are not candidates for ASCT.